Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry

被引:1
|
作者
Min, Hong Ki [1 ]
Kim, Se Hee [1 ,2 ]
Lee, Sang-Heon [3 ]
Kim, Hae-Rim [4 ]
机构
[1] Konkuk Univ, Med Ctr, Dept Internal Med, Div Rheumatol, Seoul, South Korea
[2] Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Rheumatol, Seoul, South Korea
[3] Konkuk Univ, Sch Med, Res Inst Med Sci, Div Rheumatol,Dept Internal Med,Med Ctr, Seoul, South Korea
[4] Konkuk Univ, Sch Med, Med Ctr, Div Rheumatol,Dept Internal Med,Res Inst Med Sci, 120-1 Neungdong Ro, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
biologics; DAS28; DMARDs; interstitial lung disease; rheumatoid arthritis; rheumatoid factor; AMERICAN-COLLEGE; EPIDEMIOLOGY; ABATACEPT; EVENTS;
D O I
10.1177/1759720X231218098
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Interstitial lung disease (ILD) is a critical extra-articular manifestation of rheumatoid arthritis (RA). However, little is known about the risk factors of RA-ILD.Objectives: Here, we examined the effect of demographic, clinical, therapeutic, and environmental factors on the incidence of ILD in RA patients using the Korean College of Rheumatology Biologics and Targeted Therapy (KOBIO) registry.Design: We used data from the KOBIO registry, a multi-center, prospective, observational cohort that included RA patients in South Korea.Methods: RA patients who used biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) or conventional synthetic (cs)DMARDs, and were enrolled in the KOBIO registry, were examined. Demographic, clinical, and radiographic characteristics, as well as medications, were recorded at baseline and annually thereafter. Kaplan-Meier curves and the log-rank test were used to compare the incidence of ILD between RA patients taking different b/tsDMARDs. Hazard ratios (HRs) were calculated by Cox regression analyses.Results: In total, 2492 patients (1967 in the b/tsDMARDs group and 525 in the csDMARDs group) were analyzed. The b/tsDMARDs group showed longer disease duration, higher erythrocyte sedimentation rate/C-reactive protein, and higher disease activity score-28 (DAS28) than the csDMARDs group. The incidence of ILD was significantly higher in those taking tumor necrosis factor inhibitors and abatacept than in those taking csDMARDs (log ranked p < 0.001). Multivariate Cox regression analysis identified older age (HR = 1.057, p = 0.001), male sex (HR = 2.824, p = 0.007), time-averaged DAS28 (HR = 2.241, p < 0.001), and rheumatoid factor titer (HR = 1.009, p = 0.007) as having a significantly increased HR for ILD occurrence.Conclusion: ILD is a rare but critical extra-articular symptom of RA patients. Therefore, RA patients with the above risk factors should be monitored carefully for ILD development.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis
    Suissa, Samy
    Hudson, Marie
    Ernst, Pierre
    ARTHRITIS AND RHEUMATISM, 2006, 54 (05): : 1435 - 1439
  • [32] Duration Of Rheumatoid Arthritis And The Risk Of Developing Interstitial Lung Disease
    Mohning, M.
    Yunt, Z.
    Keith, R. C.
    Olson, A.
    Perez, E. Fernandez
    Huie, T.
    Demoruelle, M.
    Goldstein, B.
    Swigris, J. J.
    Solomon, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [33] Serum Adipokines and Interstitial Lung Disease in a Prospective Rheumatoid Arthritis Cohort
    Haggart, Anna
    Baker, Joshua
    Johnson, Tate
    Yang, Yangyuna
    Roul, Punyasha
    Wysham, Katherine
    Cannon, Grant
    Kunkel, Gary
    Ascherman, Dana
    Monach, Paul
    Kerr, Gail
    Reimold, Andreas
    Duryee, Michael
    Thiele, Geoffrey
    Mikuls, Ted
    England, Bryant
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1681 - 1684
  • [34] Interstitial lung disease in rheumatoid arthritis
    Ascherman D.P.
    Current Rheumatology Reports, 2010, 12 (5) : 363 - 369
  • [35] INTERSTITIAL LUNG DISEASE IN RHEUMATOID ARTHRITIS
    Kelly, Clive
    RHEUMATOLOGY, 2014, 53 : 15 - 15
  • [36] Interstitial Lung Disease in Rheumatoid Arthritis
    Phillips, Kristine
    Flaherty, Kevin R.
    Matteson, Eric L.
    Bongartz, Tim
    Bathon, Joan
    Brown, Kevin K.
    Dellaripa, Paul F.
    CURRENT RHEUMATOLOGY REVIEWS, 2010, 6 (02) : 120 - 126
  • [37] Rheumatoid Arthritis Interstitial Lung Disease
    Solomon, J. J.
    Olson, A. L.
    Huie, T.
    Perez, E. R. Fernandez
    Mannina, A.
    Russell, G.
    Swigris, J. J.
    Fischer, A.
    Brown, K. K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [38] Rheumatoid arthritis and interstitial lung disease
    Brusselle, Guy
    RHEUMATOLOGY, 2010, 49 (08) : 1425 - 1426
  • [39] Retention Rate and Safety of Biologic or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (DMARDs) in Patients with Rheumatoid Arthritis Associated with Interstitial Lung Disease: Results from the KOBIO Registry
    Kim, Ji-Won
    Lee, Sun-Kyung
    Jung, Ju-Yang
    Suh, Chang-Hee
    Shin, Kichul
    Kim, Hyoun-Ah
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 1819 - 1821
  • [40] Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
    Kronzer, Vanessa
    Huang, Weixing
    Dellaripa, Paul
    Huang, Sicong
    Feathers, Vivi
    Lu, Bing
    Iannaccone, Christine
    Gill, Ritu
    Hatabu, Hiroto
    Nishino, Mizuki
    Crowson, Cynthia
    Davis, John
    Weinblatt, Michael
    Shadick, Nancy
    Doyle, Tracy J.
    Sparks, Jeffrey
    ARTHRITIS & RHEUMATOLOGY, 2020, 72